YIDU TECH (02158): Wins bid for the next-generation big data platform project of the First Affiliated Hospital of Chongqing Medical University
YIDU TECH (02158) announced that recently, its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. won the bid for the next-generation big data platform project of the First Affiliated Hospital of Chongqing Medical University, with a total project amount of approximately RMB13.29 million.
YIDU TECH (02158) announced that recently, its affiliate Yidu Cloud (Beijing) Technology Co., Ltd. won the bid for the next-generation big data platform project of the First Affiliated Hospital of Chongqing Medical University, with a total project amount of approximately RMB13.29 million.
YIDU TECH is a core force driving the intelligent upgrade of China's healthcare system. The group deeply empowers the entire industry chain of "medical, pharmaceutical, insurance, and patient" with intelligent decision-making, and is committed to making precision medicine benefit everyone. By simulating doctors' clinical decision-making logic, using the real disease development process as training targets, and repeatedly validating in the real world, the group has created "AI that truly understands diseases" and provides measurable value to key links in the healthcare ecosystem: enabling doctors to have more precise and efficient decision-making tools, enabling pharmaceutical companies to shorten the distance from molecules to patients, enabling patients to enjoy more affordable precision diagnosis and treatment, and enabling public systems to obtain more scientific support. YIDU TECH, with independently innovative system-level intelligence, creates a more resilient, more caring, and more inclusive and efficient future for healthcare.
Related Articles

The Pacific Shipping (02343): Kristian Helt to step down as Executive Director

FUFENG GROUP (00546) repurchased 50,000 shares on October 26 for HK$199,500.

Morgan Stanley: SINOPHARM's (01099) Q3 results reflect that the domestic industry is still under pressure; maintains "Overweight" rating with a target price of HK$22.5
The Pacific Shipping (02343): Kristian Helt to step down as Executive Director

FUFENG GROUP (00546) repurchased 50,000 shares on October 26 for HK$199,500.

Morgan Stanley: SINOPHARM's (01099) Q3 results reflect that the domestic industry is still under pressure; maintains "Overweight" rating with a target price of HK$22.5






